公开(公告)号：US20240335457A1

公开(公告)日：2024-10-10

申请号：US18587006

申请日：2024-02-26

Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC

Inventor： Colin J. MEYER ,  Warren HUFF

IPC: A61K31/56

CPC classification number: A61K31/56

Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolon.

公开(公告)号：US20240319173A1

公开(公告)日：2024-09-26

申请号：US18613041

申请日：2024-03-21

Applicant: Wisconsin Alumni Research Foundation

Inventor： James Thomson ,  Jue Zhang

IPC: G01N33/50 ,  A61K31/137 ,  A61K31/202 ,  A61K31/365 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/51 ,  A61K31/519 ,  A61K31/55 ,  A61K31/56 ,  A61K31/63 ,  A61K31/685 ,  C12N5/071 ,  C12P3/00

CPC classification number: G01N33/5073 ,  A61K31/137 ,  A61K31/202 ,  A61K31/365 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/47 ,  A61K31/51 ,  A61K31/519 ,  A61K31/55 ,  A61K31/56 ,  A61K31/63 ,  A61K31/685 ,  C12N5/069 ,  C12P3/00 ,  C12N2506/45 ,  C12N2510/00

Abstract: The present disclosure provides reagents and methods for identifying compounds that promote arterial endothelial cell differentiation and nitric oxide production therefrom. Pharmaceutical compositions comprising compounds identified thereby are provided as are therapeutic methods using these pharmaceutical compositions for treating neural and cardiovascular diseases and disorders associated with deficient or disrupted nitric oxide production in arterial endothelial cells.

公开(公告)号：US20240299448A1

公开(公告)日：2024-09-12

申请号：US18181865

申请日：2023-03-10

Applicant: Luda DIATCHENKO ,  Jeffrey MOGIL ,  Lucas Vasconcelos LIMA ,  Marc PARISIEN ,  Massimo ALLEGRI ,  Nader GHASEMLOU ,  Mohamad KARAKY

Inventor： Luda DIATCHENKO ,  Jeffrey MOGIL ,  Lucas Vasconcelos LIMA ,  Marc PARISIEN ,  Massimo ALLEGRI ,  Nader GHASEMLOU ,  Mohamad KARAKY

IPC: A61K35/15 ,  A61K31/197 ,  A61K31/485 ,  A61K31/56 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61P25/04

CPC classification number: A61K35/15 ,  A61K31/197 ,  A61K31/485 ,  A61K31/56 ,  A61K38/1866 ,  A61K38/191 ,  A61K38/2006 ,  A61K38/204 ,  A61K38/2053 ,  A61K38/208 ,  A61K38/21 ,  A61P25/04

Abstract: The present invention relates to a method of preventing or treating chronic pain comprising administering to a subject, in an amount/number effective to elicit, sustain or potentiate an inflammatory process, a pro-inflammatory compound, myeloid leukocyte cells or a substance that increases the number or activity of myeloid leukocyte cells.

公开(公告)号：US20240207288A1

公开(公告)日：2024-06-27

申请号：US18287416

申请日：2022-04-19

Applicant: Ellodi Pharmaceuticals, L.P.

Inventor： Gina EAGLE

IPC: A61K31/56 ,  A61K9/00 ,  A61K9/20 ,  A61P1/00

CPC classification number: A61K31/56 ,  A61K9/0056 ,  A61K9/2077 ,  A61P1/00

Abstract: Disclosed herein are methods for topically treating strictures by orally administering corticosteroids. Dosages, formulations, and methods for administration of corticosteroids are provided.

公开(公告)号：US12016895B2

公开(公告)日：2024-06-25

申请号：US16838338

申请日：2020-04-02

Applicant: MARY KAY INC.

Inventor： Tiffany Carle

IPC: A61K36/87 ,  A61K8/49 ,  A61K8/97 ,  A61K8/9789 ,  A61K9/00 ,  A61K9/107 ,  A61K31/05 ,  A61K31/353 ,  A61K31/56 ,  A61K31/704 ,  A61K36/23 ,  A61K36/575 ,  A61K36/82 ,  A61Q19/00 ,  A61Q19/08

CPC classification number: A61K36/87 ,  A61K8/498 ,  A61K8/97 ,  A61K8/9789 ,  A61K9/0014 ,  A61K9/107 ,  A61K31/05 ,  A61K31/353 ,  A61K31/56 ,  A61K31/704 ,  A61K36/23 ,  A61K36/575 ,  A61K36/82 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2236/30 ,  A61K36/23 ,  A61K2300/00 ,  A61K36/87 ,  A61K2300/00 ,  A61K36/575 ,  A61K2300/00 ,  A61K36/82 ,  A61K2300/00 ,  A61K31/353 ,  A61K2300/00

Abstract: A method of treating telangiectasia in a subject in need thereof is disclosed. The method includes topically applying to skin of said subject in need of treatment of telangiectasia a composition comprising effective amounts of an extract of Centella asiatica leaf and an extract of Vitis vinifera seed to disrupt endothelial tubes in skin.

公开(公告)号：US11986491B2

公开(公告)日：2024-05-21

申请号：US14127846

申请日：2011-06-22

Applicant: Bo Liang ,  Belachew Tessema ,  Joseph A. Capriotti ,  Michael C. Samson ,  Wei Song

Inventor： Bo Liang ,  Belachew Tessema ,  Joseph A. Capriotti ,  Michael C. Samson ,  Wei Song

IPC: A61K31/79 ,  A61K9/00 ,  A61K31/38 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61P11/00

CPC classification number: A61K31/79 ,  A61K9/0043 ,  A61K31/38 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58

Abstract: The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same.

公开(公告)号：US20240148751A1

公开(公告)日：2024-05-09

申请号：US18046194

申请日：2022-10-13

Applicant: Hong Kong Baptist University

Inventor： Zhaoxiang BIAN ,  Tao HUNG ,  Ling ZHAO ,  Lidan ZHONG ,  Chengyuan LIN

IPC: A61K31/56 ,  A61K36/732 ,  A61P9/00

CPC classification number: A61K31/56 ,  A61K36/732 ,  A61P9/00

Abstract: A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.

公开(公告)号：US20240148686A1

公开(公告)日：2024-05-09

申请号：US18278628

申请日：2021-04-26

Applicant: CHINA PHARMACEUTICAL UNIVERSITY

Inventor： Liang WU

IPC: A61K31/352 ,  A61K31/56 ,  A61P1/16

CPC classification number: A61K31/352 ,  A61K31/56 ,  A61P1/16

Abstract: The present disclosure relates to a pharmaceutical composition, including a first component and a second component, where the first component is selected from the group consisting of forskolin, isoforskolin, and a pharmaceutically acceptable salt thereof; and the second component is selected from the group consisting of a pentacyclic triterpenoid and a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present disclosure allows the combined use of forskolin-isoforskolin with a pentacyclic triterpenoid. Compared with the use of each of the two components alone, the combined use can play a significant synergistic role in prevention and treatment of a metabolic disease, a fibrotic disease, and a liver disease. Therefore, the pharmaceutical composition of the present disclosure has promising medicinal prospects in treatment, prevention, and improvement of obesity, a non-alcoholic fatty liver disease (NAFLD), liver damage, liver fibrosis, and the like.

公开(公告)号：US11974977B2

公开(公告)日：2024-05-07

申请号：US17338338

申请日：2021-06-03

Applicant: LUCOLAS—M.D. LTD

Inventor： Alfred Schmidt

IPC: A61K8/63 ,  A61K8/9755 ,  A61K8/9789 ,  A61K8/9794 ,  A61K31/215 ,  A61K31/56 ,  A61K31/5685 ,  A61K36/13 ,  A61K36/185 ,  A61K36/19 ,  A61K36/25 ,  A61K36/31 ,  A61K36/32 ,  A61K36/42 ,  A61K36/48 ,  A61K36/889 ,  A61K45/06 ,  A61Q5/08 ,  A61Q7/00 ,  A61Q7/02

CPC classification number: A61K31/215 ,  A61K8/63 ,  A61K8/9755 ,  A61K8/9789 ,  A61K8/9794 ,  A61K31/56 ,  A61K31/5685 ,  A61K36/13 ,  A61K36/185 ,  A61K36/19 ,  A61K36/25 ,  A61K36/31 ,  A61K36/32 ,  A61K36/42 ,  A61K36/48 ,  A61K36/889 ,  A61K45/06 ,  A61Q5/08 ,  A61Q7/00 ,  A61Q7/02 ,  A61K2800/782 ,  A61K31/5685 ,  A61K2300/00 ,  A61K36/13 ,  A61K2300/00 ,  A61K36/185 ,  A61K2300/00 ,  A61K36/19 ,  A61K2300/00 ,  A61K36/25 ,  A61K2300/00 ,  A61K36/31 ,  A61K2300/00 ,  A61K36/32 ,  A61K2300/00 ,  A61K36/42 ,  A61K2300/00 ,  A61K36/48 ,  A61K2300/00 ,  A61K36/889 ,  A61K2300/00

Abstract: The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

公开(公告)号：US20240139146A1

公开(公告)日：2024-05-02

申请号：US18224122

申请日：2023-07-20

Applicant: Sanofi Mature IP

Inventor： Sunil GUPTA

IPC: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K38/19 ,  A61K45/06

CPC classification number: A61K31/337 ,  A61K31/164 ,  A61K31/56 ,  A61K31/573 ,  A61K38/193 ,  A61K45/06

Abstract: The invention relates to a compound of formula:




which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.